ストックスクリーナーアプリを入手
3.31
2.48%
0.08
アフターアワーズ：
3.31
前日終値:
$3.23
開ける：
$3.186
24時間の取引高:
10,945
Relative Volume:
0.33
時価総額：
$14.40M
収益：
-
当期純損益:
$-60.61M
株価収益率:
-3.6778
EPS:
-0.9
ネットキャッシュフロー:
$-22.91M
1週間 パフォーマンス:
-2.07%
1か月 パフォーマンス:
-4.89%
6か月 パフォーマンス:
-37.43%
1年 パフォーマンス:
+1,371%
1日の値動き範囲:
$3.141
$3.31
1週間の範囲:
$3.141
$3.4299
52週間の値動き範囲:
$0.0815
$7.7699
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
BLRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
3.31 | 14.05M | 0 | -60.61M | -22.91M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2017-05-18 | アップグレード | Maxim Group | Hold → Buy |
| 2017-02-13 | 開始されました | Rodman & Renshaw | Buy |
| 2016-08-12 | ダウングレード | Maxim Group | Buy → Hold |
| 2015-08-17 | 繰り返されました | Maxim Group | Buy |
| 2015-07-27 | 繰り返されました | ROTH Capital | Buy |
| 2015-06-22 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Bioline Rx Ltd Adr (BLRX) 最新ニュース
BioLineRx Earnings Call: Strategic Initiatives Amid Revenue Challenges - MSN
BioLineRx Reports Q3 2025 Results and Strategic Expansion - TipRanks
Earnings call transcript: BioLineRx Q3 2025 earnings reveal significant revenue miss By Investing.com - Investing.com South Africa
BioLineRx Announces Q3 2025 Financial Results and New Joint Venture - TipRanks
Earnings call transcript: BioLineRx Q3 2025 earnings reveal significant revenue miss - Investing.com India
BioLineRx shares rise over 7% on better-than-expected earnings By Investing.com - Investing.com South Africa
BioLineRx shares rise over 7% on better-than-expected earnings - Investing.com
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Finviz
Options Volatility and Implied Earnings Moves Today, November 24, 2025 - TipRanks
BioLine Rx's Earnings: A Preview - Sahm
BioLineRx stock rises after partner receives key patent allowance By Investing.com - Investing.com India
BioLineRx stock rises after partner receives key patent allowance - Investing.com
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 - Finviz
BioLineRx stock rises after securing key patent for cancer treatment - Investing.com India
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types - Finviz
BioLineRx Secures USPTO Patent Allowance for Cancer Treatment with GLIX1 - TipRanks
BioLineRx receives key patent for cancer treatment GLIX1 - Investing.com India
BioLineRx receives key patent for cancer treatment GLIX1 By Investing.com - Investing.com South Africa
Analysts’ Top Healthcare Picks: Serina Therapeutics (SER), Cybin (CYBN) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Beyond Air (XAIR), Diamedica Therapeutics (DMAC) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Lexicon Pharmaceuticals (LXRX) and Cullinan Management (CGEM) - The Globe and Mail
Working capital per share of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
BioLineRx ADR Earnings Call: Optimism Amid Challenges - MSN
Analysts Are Bullish on Top Healthcare Stocks: Abbott Laboratories (ABT), Achieve Life Sciences (ACHV) - The Globe and Mail
Cash per share of BioLineRX Ltd. Sponsored ADR – FWB:YP2 - TradingView
BioLineRx, Hemispherian AS establish joint venture to develop GLIX1 - TipRanks
BioLineRx and Hemispherian Launch Joint Venture to Develop GLIX1 for Glioblastoma - TipRanks
BioLineRx and Hemispherian form joint venture to develop brain cancer drug - Investing.com
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers - Sahm
BioLineRx (NASDAQ:BLRX) Stock Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
Earnings call transcript: BioLineRx Q2 2025 sees restructuring and innovation - Investing.com
BioLineRx: Strategic Pipeline Expansion and Strong Financial Health Justify Buy Rating - TipRanks
BioLineRx Ltd. Reports Q2 2025 Financial Results - TipRanks
BioLineRx Reports Q2 2025 Financials and Strategic Updates - MSN
BioLineRx To Report Second Quarter 2025 Results On August 14, 2025 - Barchart.com
BioLineRx: Promising Financial Position and Strategic Initiatives Drive Buy Rating - TipRanks
BioLineRx Reports Second Quarter 2025 Financial Results And Provides Corporate Update - Barchart.com
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Esperion (ESPR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC), Lexaria Bioscience (LEXX) and Travere Therapeutics (TVTX) - The Globe and Mail
H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. (BLRX) After ASCO 2025 - Finviz
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Processa Pharmaceuticals (PCSA) and Clene (CLNN) - The Globe and Mail
BioLineRx Ltd. Approves Key Proposals at Annual Meeting - TipRanks
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Capricor Therapeutics (CAPR) and Abbott Laboratories (ABT) - The Globe and Mail
Promising Phase 2 Trial Results Drive Buy Rating for BioLine RX in mPDAC Treatment - TipRanks
BioLineRx ADR: Positive Earnings Call Highlights and Challenges - MSN
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
BioLineRx upgraded to Buy from Hold at JonesResearch - Yahoo Finance
Bioline Rx Ltd Adr (BLRX) 財務データ
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):